8 March 2016 - Despite receiving an extra $1 billion in fees from the generic drug user fee program, the FDA has slowed the pace at which it approves generic drugs, leading to less competition and higher costs for consumers, according to Lamar Alexander (R, Tenn), chair of the Senate health committee, at a recent hearing.

For more details, go to: http://jama.jamanetwork.com/article.aspx?articleID=2499254&utm_source=Silverchair_Information_Systems&utm_campaign=Tuesday_March_8_2016&utm_content=eTOC&cmp=1&utm_medium=email